What is Grace Therapeutics, Inc. Common Stock's Market Cap?

Grace Therapeutics, Inc. Common Stock's Market Cap is $44.6M, based on as-reported figures from SEC (XBRL) filings.

What is Grace Therapeutics, Inc. Common Stock's Enterprise Value?

Grace Therapeutics, Inc. Common Stock's Enterprise Value is $30.8M, based on as-reported figures from SEC (XBRL) filings.

What is Grace Therapeutics, Inc. Common Stock's EV / EBITDA?

Grace Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Grace Therapeutics, Inc. Common Stock's Net Income (TTM)?

Grace Therapeutics, Inc. Common Stock's Net Income (TTM) is -$20.2M, based on as-reported figures from SEC (XBRL) filings.

What is Grace Therapeutics, Inc. Common Stock's EBITDA?

Grace Therapeutics, Inc. Common Stock's EBITDA is -$23.9M, based on as-reported figures from SEC (XBRL) filings.

What is Grace Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?

Grace Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.96, based on as-reported figures from SEC (XBRL) filings.

What is Grace Therapeutics, Inc. Common Stock's Net Debt?

Grace Therapeutics, Inc. Common Stock's Net Debt is -$13.8M, based on as-reported figures from SEC (XBRL) filings.

Grace Therapeutics, Inc. Common Stock (GRCE) Financial Statements

Grace Therapeutics, Inc. Common Stock

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG001SFYCM5

XNAS · usd

2.12▲ 0.02 (0.95%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales—

EV / Revenue—

EV / EBITDA

Financial Highlights

Revenue (TTM)—

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin—

Net Debt

Trading Information

Previous Close2.10

Day's Range2.05 – 2.14

52-Week Range1.79 – 5.18

Volume159.4K

Avg Volume200.7K

Share Statistics

Shares Outstanding

Employees6

ExchangeXNAS

Listed2011-04-26

Share count as of August 11, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Grace Therapeutics, Inc. Common Stock (GRCE)

What is Grace Therapeutics, Inc. Common Stock's Market Cap?: Grace Therapeutics, Inc. Common Stock's Market Cap is $44.6M, based on as-reported figures from SEC (XBRL) filings.
What is Grace Therapeutics, Inc. Common Stock's Enterprise Value?: Grace Therapeutics, Inc. Common Stock's Enterprise Value is $30.8M, based on as-reported figures from SEC (XBRL) filings.
What is Grace Therapeutics, Inc. Common Stock's EV / EBITDA?: Grace Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Grace Therapeutics, Inc. Common Stock's Net Income (TTM)?: Grace Therapeutics, Inc. Common Stock's Net Income (TTM) is -$20.2M, based on as-reported figures from SEC (XBRL) filings.
What is Grace Therapeutics, Inc. Common Stock's EBITDA?: Grace Therapeutics, Inc. Common Stock's EBITDA is -$23.9M, based on as-reported figures from SEC (XBRL) filings.
What is Grace Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?: Grace Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.96, based on as-reported figures from SEC (XBRL) filings.
What is Grace Therapeutics, Inc. Common Stock's Net Debt?: Grace Therapeutics, Inc. Common Stock's Net Debt is -$13.8M, based on as-reported figures from SEC (XBRL) filings.